Retinoic acid-induced developmental defects are mediated by RARβ/RXR heterodimers in the pharyngeal endoderm
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Fusion and hypoplasia of the first two branchial arches, a defect typically observed in retinoic acid (RA) embryopathy, is generated in cultured mouse embryos upon treatment with BMS453, a synthetic compound that exhibits retinoic acid receptor β (RARβ) agonistic properties in transfected cells. By contrast, no branchial arch defects are observed following treatment with synthetic retinoids that exhibit RARα or RARγ agonistic properties. The BMS453-induced branchial arch defects are mediated through RAR activation, as they are similar to those generated by a selective pan-RAR agonist, are prevented by a selective pan-RAR antagonist and cannot be mimicked by exposure to a pan-RXR agonist alone. They are enhanced in the presence of a pan-RXR agonist, and cannot be generated in Rarb-null embryos. Furthermore, they are accompanied, in the morphologically altered region, by ectopic expression of Rarb and of several other direct RA target genes. Therefore, craniofacial abnormalities characteristic of the RA embryopathy are mediated through ectopic activation of RARβ/RXR heterodimers, in which the ligand-dependent activity of RXR is subordinated to that of RARβ. Endodermal cells lining the first two branchial arches respond to treatment with the RARβ agonist, in contrast to neural crest cells and ectoderm, which suggests that a faulty endodermal regionalization is directly responsible for RA-induced branchial arch dysmorphologies. Additionally, we provide the first in vivo evidence that the synthetic RARβ agonist BMS453 exhibits an antagonistic activity on the two other RAR isotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A decade of molecular biology of retinoic acid receptors
Chambon, P. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.9.8801176 · Cited by 2,889 · cited 3×
“…RARs, whereas only 9-cis RA activates RXRs. RARs and RXRs function as ligand-dependent transregulators by binding, in the form of RAR/RXR heterodimers, to RA response elements (RARE) located in the regulatory regions of target genes (reviewed by Chambon, 1996; Laudet and Gronemeyer, 2002).”
BackgroundSelf-citationLammer, E. J., Chen, D. T., Hoar, R. M., Agnish, N. D., Benke, P. J., Braun, J. T., Curry, C. J., Fernhoff, P. M., Grix, A. W., Lott, I. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510033131401 · Cited by 1,942
The promise of retinoids to fight against cancer
Altucci, L., & Gronemeyer, H. (2001) · Nature Reviews Cancer · doi:10.1038/35106036 · Cited by 773
Cited by
Principles for modulation of the nuclear receptor superfamily
Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,226
Mark, M., Ghyselinck, N. B., & Chambon, P. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141156 · Cited by 593
Self-citationMinoux, M., & Rijli, F. M. (2010) · Development · doi:10.1242/dev.040048 · Cited by 507
“However, the endoderm could be the primary target of RA action in mediating morphogenesis of PA2 and more posterior arches (Matt et al., 2003), as RARs are mostly dispensable in cranial NCCs (Dupe and Pellerin, 2009).”
BackgroundFunction of retinoic acid receptors during embryonic development
Mark, M., Ghyselinck, N. B., & Chambon, P. (2009) · Nuclear Receptor Signaling · doi:10.1621/nrs.07002 · Cited by 363
Self-citationDupé, V., Matt, N., Garnier, J.-M., Chambon, P., Mark, M., & Ghyselinck, N. B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2336223100 · Cited by 315
Self-citationLIGAND CONTROL OF COREGULATOR RECRUITMENT TO NUCLEAR RECEPTORS
Nettles, K. W., & Greene, G. L. (2005) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.032802.154710 · Cited by 268
Retinoic Acid Induces Blood–Brain Barrier Development
Mizee, M. R., Wooldrik, D., Lakeman, K. A. M., van het Hof, B., Drexhage, J. A. R., Geerts, D., Bugiani, M., Aronica, E., Mebius, R. E., Prat, A., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1338-12.2013 · Cited by 203
“BMS453 has confirmed activity in vitro (Germain et al., 2004) and in vivo (Matt et al., 2003).”
BackgroundDefinitive endoderm of the mouse embryo: Formation, cell fates, and morphogenetic function
Lewis, S. L., & Tam, P. P. L. (2006) · Developmental Dynamics · doi:10.1002/dvdy.20846 · Cited by 164
“Treatment with a RAR agonist results in defects in pharyngeal arches 1 and 2 attributable to ectopic expression of Hoxb1/Hoxa1 in the anterior pharyngeal endoderm (Matt et al., 2003).”
Background
Metadata
- Authors
- Matt, N., Ghyselinck, N. B., Wendling, O., Chambon, P., & Mark, M.
- Venue
- Development
- Publisher
- The Company of Biologists
- Published
- 2003-05-15
- Volume
- 130
- Issue
- 10
- Pages
- 2083-2093
- ISSN
- 0950-1991 (ISSN-L)
- 1477-9129
- OpenAlex
- W1981279981
- Cited by
- 109
- References
- 3
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.